Rigel Pharmaceuticals | RIGL - Ingresos Por Ventas





Ventas Cambio Fecha
Agenus USD 34.2M 3.97M 2025-12
Amgen USD 8.62B 1.28B 2026-03
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 15.29B 213M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Celldex Therapeutics USD 121K 769K 2025-12
Daiichi Sankyo JPY 587B 28.89B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Intrexon USD 717K 511K 2024-06
Ionis Pharmaceuticals USD 246M 43M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Veracyte USD 139.07M 1.53M 2026-03